Cara Therapeutics, Inc.

CARA


Canadian symbol: CARA
US symbol: CARA

Currency in USD

Valuation Measures4

Market Cap (intraday) 189.48M
Enterprise Value 76.65M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)4.36
Price/Book (mrq)1.39
Enterprise Value/Revenue 1.77
Enterprise Value/EBITDA -0.88

Trading Information

Stock Price History

Beta (5Y Monthly) 0.87
52-Week Change 3-59.13%
S&P500 52-Week Change 31.77%
52 Week High 312.9800
52 Week Low 33.2400
50-Day Moving Average 34.3726
200-Day Moving Average 38.8830

Share Statistics

Avg Vol (3 month) 3766.14k
Avg Vol (10 day) 3959.81k
Shares Outstanding 553.98M
Implied Shares Outstanding 6N/A
Float 845.3M
% Held by Insiders 114.37%
% Held by Institutions 165.33%
Shares Short (May 14, 2023) 45.01M
Short Ratio (May 14, 2023) 49.96
Short % of Float (May 14, 2023) 413.01%
Short % of Shares Outstanding (May 14, 2023) 49.28%
Shares Short (prior month Apr 13, 2023) 44.84M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2022
Most Recent Quarter (mrq)Mar 30, 2023

Profitability

Profit Margin -195.16%
Operating Margin (ttm)-201.83%

Management Effectiveness

Return on Assets (ttm)-28.93%
Return on Equity (ttm)-49.54%

Income Statement

Revenue (ttm)43.24M
Revenue Per Share (ttm)0.81
Quarterly Revenue Growth (yoy)28.70%
Gross Profit (ttm)-56.14M
EBITDA -87.03M
Net Income Avi to Common (ttm)-84.39M
Diluted EPS (ttm)-1.5100
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)114.28M
Total Cash Per Share (mrq)2.12
Total Debt (mrq)1.46M
Total Debt/Equity (mrq)1.07
Current Ratio (mrq)8.55
Book Value Per Share (mrq)2.53

Cash Flow Statement

Operating Cash Flow (ttm)-87.82M
Levered Free Cash Flow (ttm)-56.47M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
CARA
Cara Therapeutics
1 day ago
CARA
Cara Therapeutics
2 weeks ago
CARA
Cara Therapeutics
2 weeks ago
CARA
Cara Therapeutics
4 weeks ago
CARA
Cara Therapeutics
1 month ago
CARA
Cara Therapeutics
1 month ago
CARA
Cara Therapeutics
2 months ago
CARA
Cara Therapeutics
2 months ago
CARA
Cara Therapeutics
2 months ago
CARA
Cara Therapeutics
2 months ago
CARA
Cara Therapeutics
2 months ago
CARA
Cara Therapeutics
2 months ago
CARA
Cara Therapeutics
3 months ago
CARA
Cara Therapeutics
4 months ago
CARA
Cara Therapeutics
4 months ago
CARA
Cara Therapeutics
4 months ago
CARA
Cara Therapeutics
6 months ago
CARA
Cara Therapeutics
6 months ago
CARA
Cara Therapeutics
6 months ago
CARA
Cara Therapeutics
6 months ago
CARA
Cara Therapeutics
7 months ago
CARA
Cara Therapeutics
8 months ago
CARA
Cara Therapeutics
9 months ago
CARA
Cara Therapeutics
11 months ago
CARA
Cara Therapeutics
11 months ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
1 year ago
CARA
Cara Therapeutics
2 years ago
CARA
Cara Therapeutics
2 years ago
CARA
Cara Therapeutics
2 years ago
CARA
Cara Therapeutics
2 years ago
CARA
Cara Therapeutics
2 years ago
CARA
Cara Therapeutics
2 years ago
CARA
Cara Therapeutics
2 years ago
CARA
Cara Therapeutics
2 years ago
CARA
Cara Therapeutics
2 years ago
CARA
Cara Therapeutics
2 years ago
CARA
Cara Therapeutics
2 years ago
CARA
Cara Therapeutics
2 years ago
CARA
Cara Therapeutics
2 years ago
CARA
Cara Therapeutics
2 years ago
CARA
Cara Therapeutics
2 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
3 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago
CARA
Cara Therapeutics
4 years ago

Currency in USD
Earnings EstimateCurrent Qtr. (Jun 2023)Next Qtr. (Sep 2023)Current Year (2023)Next Year (2024)
No. of Analysts6677
Avg. Estimate-0.51-0.46-1.8-1.02
Low Estimate-0.6-0.62-2.21-1.68
High Estimate-0.44-0.23-1.31-0.6
Year Ago EPS-0.08-0.43-1.59-1.8
Revenue EstimateCurrent Qtr. (Jun 2023)Next Qtr. (Sep 2023)Current Year (2023)Next Year (2024)
No. of Analysts6677
Avg. Estimate7.65M14.24M49.02M97.9M
Low Estimate6.4M9.3M38.8M70.5M
High Estimate9.5M22M64.1M134.29M
Year Ago Sales23M10.81M41.87M49.02M
Sales Growth (year/est)-66.70%31.70%17.10%99.70%
Earnings History2022-06-292022-09-292022-12-302023-03-30
EPS Est.-0.25-0.42-0.32-0.52
EPS Actual-0.08-0.43-0.56-0.49
Difference0.17-0.01-0.240.03
Surprise %68.00%-2.40%-75.00%5.80%
EPS TrendCurrent Qtr. (Jun 2023)Next Qtr. (Sep 2023)Current Year (2023)Next Year (2024)
Current Estimate-0.51-0.46-1.8-1.02
7 Days Ago-0.51-0.46-1.8-1.02
30 Days Ago-0.52-0.41-1.74-0.75
60 Days Ago-0.52-0.41-1.74-0.75
90 Days Ago-0.2-0.11-0.760.17
EPS RevisionsCurrent Qtr. (Jun 2023)Next Qtr. (Sep 2023)Current Year (2023)Next Year (2024)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 Days3142
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesCARAIndustrySector(s)S&P 500
Current Qtr.-537.50%N/AN/AN/A
Next Qtr.-7.00%N/AN/AN/A
Current Year-13.20%N/AN/AN/A
Next Year43.30%N/AN/AN/A
Next 5 Years (per annum)110.70%N/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in USD
Breakdown
14.37%% of Shares Held by All Insider
65.33%% of Shares Held by Institutions
76.29%% of Float Held by Institutions
234Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Blackrock Inc.7,602,683Mar 30, 202314.08%26,153,229
Vanguard Group, Inc. (The)3,122,826Mar 30, 20235.78%10,742,521
Bain Capital Life Sciences Investors, LLC2,204,449Mar 30, 20234.08%7,583,304
Farallon Capital Management Llc1,995,370Mar 30, 20233.70%6,864,072
State Street Corporation1,902,942Mar 30, 20233.53%6,546,120
Disciplined Growth Investors, Inc.1,732,375Mar 30, 20233.21%5,959,370
Kingdon Capital Management LLC1,233,000Mar 30, 20232.28%4,241,520
Chescapmanager LLC1,160,392Mar 30, 20232.15%3,991,748
Dimensional Fund Advisors LP945,882Mar 30, 20231.75%3,253,834
Geode Capital Management, LLC892,319Mar 30, 20231.65%3,069,577

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
iShares Core S&P Smallcap ETF3,404,444Feb 27, 20236.31%11,711,287
Vanguard Total Stock Market Index Fund1,354,313Dec 30, 20222.51%4,658,836
iShares Russell 2000 ETF980,456Feb 27, 20231.82%3,372,768
Vanguard Extended Market Index Fund632,487Dec 30, 20221.17%2,175,755
iShares S&P Small-Cap 600 Growth ETF500,854Feb 27, 20230.93%1,722,937
iShares Russell 2000 Value ETF454,984Feb 27, 20230.84%1,565,144
Vanguard Tax Managed Fund-Small Cap Fund409,291Dec 30, 20220.76%1,407,961
Fidelity Small Cap Index Fund372,842Jan 30, 20230.69%1,282,576
iShares NASDAQ Biotechnology ETF336,647Feb 27, 20230.62%1,158,065
USAA Mutual Fund Tr-Science & Technology Fund321,160Jan 30, 20230.60%1,104,790
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Cara Therapeutics, Inc.


Kapruvia® (difelikefalin) recommended by England's NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus

<!-- Name:DistributionId Value:8841838 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 --> <!-- Name:CustomerId Value:1017612 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:f0860ce4-3b98-475e-973c-1596b7389169 --> ST. GALLEN, Sw... Read More...
Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine

Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine

<!-- Name:DistributionId Value:8745441 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 --> <!-- Name:CustomerId Value:1017612 --> <!-- Name:HasMediaSnippet Value:false --> <!-- Name:AnalyticsTrackingId Value:c508cf14-bf59-457c-b82a-7b0f74a79aed --> STAMFORD, Conn... Read More...
Cara Therapeutics Reports Third Quarter 2022 Financial Results

Cara Therapeutics Reports Third Quarter 2022 Financial Results

– Net revenue was $16.2M for 3Q22 including profit-sharing revenue of $7.4M from KORSUVA® (difelikefalin) injection – – Strong demand for KORSUVA injection driven by large dialysis organizations with ~180,000 vials shipped – – FDA meeting scheduled in 4Q22 to discuss potential pivotal program in notalgia paresthetica – – Conference call t... Read More...
Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022

Cara Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022

STAMFORD, Conn., Oct. 24, 2022 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, November 7, 2022, at 4:30 p.m. ET to rep... Read More...
Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan

Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan

STAMFORD, Conn., Sept. 28, 2022 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that its licensing partner Maruishi Pharmaceutical Co., Ltd. submitted a New Drug Application (NDA) in Japan for ... Read More...
Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress

Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress

– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Significant reduction of itch intensity was evident at Day 1 and effect was maintained through Week 8 – – Significantly greater proportion of patients who received oral difelikefalin vs. placebo achieved a complete respo... Read More...
Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

STAMFORD, Conn., Sept. 06, 2022 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the H.C. Wainwright 24th Annual G... Read More...
Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022

Cara Therapeutics to Host Virtual Notalgia Paresthetica Event on September 20, 2022

STAMFORD, Conn., Aug. 24, 2022 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a virtual event focused on notalgia paresthetica (NP) on Tuesday, September 20, 2022, from 1... Read More...
Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress

Cara Therapeutics Announces KOMFORT Data Accepted for Late-Breaking Presentation at the 31st EADV Congress

STAMFORD, Conn., Aug. 22, 2022 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced data from the KOMFORT Phase 2 clinical trial evaluating oral difelikefalin for the treatment of moderate-to-severe... Read More...
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022

Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022

Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients Therapy recently approved in Canada under the brand name KORSUVA® Regulatory decisions in Australia and Singapore expected by the end of 2022 ST. GALLEN, ... Read More...
Cara Therapeutics Reports Second Quarter 2022 Financial Results

Cara Therapeutics Reports Second Quarter 2022 Financial Results

– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia® (difelikefalin) – – KOMFORT Phase 2 trial met primary endpoint in notalgia paresthetica, validating potential broad utility of oral difelikefa... Read More...
Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022

Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022

STAMFORD, Conn., Aug. 01, 2022 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, August 8, 2022, at 4:30 p.m. ET to repor... Read More...
Cara Therapeutics Reports First Quarter 2022 Financial Results

Cara Therapeutics Reports First Quarter 2022 Financial Results

KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients, triggering $15M milestone payment to Cara Top-line da... Read More...
Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022

Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022

STAMFORD, Conn., April 29, 2022 -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, May 9, 2022, at 4:30 p.m. ET to ... Read More...
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patientsFirst launches in Europe expected in H2 2022 ST. GALLEN, Switzerland and STAMFORD, Conn., April 28, 2022 --  Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today anno... Read More...
Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

STAMFORD, Conn., April 05, 2022 -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will participate in a fireside chat at the... Read More...
Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022

Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022

STAMFORD, Conn., April 04, 2022 -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced biomarker data from the KALM-1 and KALM-2 clinical trials evaluating KORSUVA™ (difelikefalin) injection fo... Read More...
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus

STAMFORD, Conn., March 28, 2022 -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced data from a sub-study of the KARE Phase 2 clinical trial demonstrated Oral KORSUVA™ (difelikefalin) improv... Read More...
Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting

Oral presentation will include biomarker data from KARE Phase 2 clinical trial of Oral KORSUVA™ (difelikefalin) for the treatment of moderate-to-severe pruritus in atopic dermatitis patients Oral KORSUVA (difelikefalin) Phase 3 pruritus programs in non-dialysis dependent advanced chronic kidney disease and atopic dermatitis, respectively,... Read More...
Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

KORSUVA™ (difelikefalin) injection U.S. commercial launch on track for April 2022 with extensive pre-launch activities completed Initiation of Oral KORSUVA (difelikefalin) Phase 3 pruritus programs in non-dialysis dependent advanced chronic kidney disease and atopic dermatitis expected in 1Q 2022 Phase 3 programs to be highlighted in virt... Read More...
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients

Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients

Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia® (difelikefalin) as first therapy in Europe for the treatment of chronic kidney disease associated-pruritus (CKD-aP) in hemodialysis patientsEuropean Commission decision for EU Marketing Authorization is expected in Q2 2022Kapruvia® is approved in the U.... Read More...
Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

STAMFORD, Conn., Feb. 22, 2022 -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Tuesday, March 1, 2022, at 4:30 p.m. ET t... Read More...
Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

STAMFORD, Conn., Jan. 03, 2022 -- Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present a company overview at the 40th... Read More...
Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection

Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection

KORSUVA receives TDAPA reimbursement beginning April 2022 U.S. commercial launch on track for early second quarter 2022 STAMFORD, Conn., Dec. 20, 2021 -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted Transitional Drug Add-On Payment Adjustment (TDAPA) to... Read More...
Cara Therapeutics Reports Third Quarter 2021 Financial Results

Cara Therapeutics Reports Third Quarter 2021 Financial Results

– KORSUVA™ (CR845/difelikefalin) injection Approved as First and Only Treatment for Chronic Kidney Disease-associated Pruritus (CKD-aP) in Adult Hemodialysis Patients by U.S. Food and Drug Administration (FDA) – – Christopher Posner Appointed President and Chief Executive Officer Effective November 9th, 2021 – – Conference call today at 4... Read More...
Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021

Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021

STAMFORD, Conn., Nov. 01, 2021 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast... Read More...
Cara Therapeutics Presents Late-Breaking Results of KARE Phase 2 Trial of Oral Difelikefalin (Oral KORSUVA™) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

Cara Therapeutics Presents Late-Breaking Results of KARE Phase 2 Trial of Oral Difelikefalin (Oral KORSUVA™) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

STAMFORD, Conn., Oct. 04, 2021 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, presented results from the KARE Phase 2 clinical trial of oral difelikefalin for th... Read More...
Cara Therapeutics Announces Late-Breaking Presentation at 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

Cara Therapeutics Announces Late-Breaking Presentation at 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

STAMFORD, Conn., Sept. 29, 2021 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced that results from the KARE Phase 2 clinical trial of Oral K... Read More...
Cara Therapeutics to Present at the the 2021 Cantor Virtual Global Healthcare Conference

Cara Therapeutics to Present at the the 2021 Cantor Virtual Global Healthcare Conference

STAMFORD, Conn., Sept. 24, 2021 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs), today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Exec... Read More...
Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis Promotional launch of KORSUVA™ injection in the U.S. is expected in Q1 2022, with reimbursement in H1 2022Company to host conference call today at 5.00 p.m. ET STAMFORD, Conn. and ST. G... Read More...
Cara Therapeutics Reports Second Quarter 2021 Financial Results

Cara Therapeutics Reports Second Quarter 2021 Financial Results

– New Drug Application (NDA) Filing for KORSUVA™ Injection in CKD-aP under Priority Review by U.S. Food and Drug Administration (FDA); PDUFA Target Action Date August 23, 2021 – – Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Aug. 09, 2021 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on develop... Read More...
Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021

Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021

STAMFORD, Conn., Aug. 02, 2021 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast... Read More...
Cara Therapeutics Reports First Quarter 2021 Financial Results

Cara Therapeutics Reports First Quarter 2021 Financial Results

– U.S. Food and Drug Administration (FDA) Accepts New Drug Application (NDA) Filing and Grants Priority Review for KORSUVA™ Injection in CKD-aP – – Conference call today at 4:30 p.m. ET – STAMFORD, Conn., May 10, 2021 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemi... Read More...
Cara Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

Cara Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

STAMFORD, Conn., May 06, 2021 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Off... Read More...
Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021

Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021

STAMFORD, Conn., May 03, 2021 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast ... Read More...
Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

       – Study did not meet Primary Endpoint of worst-itch NRS change from baseline at        week 12 or Secondary Endpoint of 4-point responder analysis in the ITT patient population        – Study achieved Primary Endpoint of worst-itch NRS change and Secondary Endpoint of 4-point responder analysis in pre-specified analyses of mild-to-... Read More...
Cara Therapeutics to Present at the 20th Annual Needham Healthcare Conference

Cara Therapeutics to Present at the 20th Annual Needham Healthcare Conference

STAMFORD, Conn., April 07, 2021 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Ex... Read More...
Cara Therapeutics to Host Virtual Research and Development Event on April 7, 2021

Cara Therapeutics to Host Virtual Research and Development Event on April 7, 2021

STAMFORD, Conn., March 31, 2021 -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that the Company will host a virtual research and develop... Read More...
VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin

VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin

Companies have successfully submitted the EU regulatory application for marketing authorization for difelikefalinIf approved, difelikefalin injection will be the first therapy available in Europe for treatment of pruritus associated with chronic kidney disease in hemodialysis patients ST. GALLEN, Switzerland and STAMFORD, Conn., March 30... Read More...
Cara Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus

Cara Therapeutics and Vifor Pharma announce U.S. FDA acceptance and Priority Review of NDA for KORSUVA™* injection in hemodialysis patients with moderate-to-severe pruritus

FDA has set Prescription Drug User Fee Act (PDUFA) target action date of August 23, 2021If approved, KORSUVA™ injection would be first therapy for treatment of pruritus in hemodialysis patientsSTAMFORD, Conn, and ST. GALLEN, Switzerland, March 08, 2021 -- Cara Therapeutics (Nasdaq:CARA) and Vifor Pharma today announced that the U.S. Food ... Read More...
Coming Soon.
IndexLast% Change
S&P 5003,902.62--
Euro STOXX 503,495.98

0.21%Positive

FTSE 1007,164.40

0.34%Negative

Nikkei 22526,517.19

0.10%Positive


Delayed data (1h)
IndexLast% Change
S&P 5003,902.62--
Euro STOXX 503,495.98

0.21%Positive

FTSE 1007,164.40

0.34%Negative

Nikkei 22526,517.19

0.10%Positive



Share this page